HC2 Biosimilars Versus Brands for Rheumatoid Arthritis: Eu5 Payers and Prescribers Place their Bets  by Cox, J. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A325
Objectives: A binary reimbursement prediction model was previously developed 
based on a dataset of submissions to the Scottish Medicines Consortium (SMC) 
between 2006 and 2014. The objective of this study is to build on the previous model 
by identifying factors that influence the different levels of SMC recommendation, 
defined as “recommend”, “restrict” or “not recommend” pharmaceutical technolo-
gies for use in Scotland. MethOds: Univariate and multivariate ordered logistic 
regression analyses were performed to assess the impact by means of odds ratios 
(OR) of the submitted evidence to the SMC on the decision. The proportional odds 
assumption underlying the current approach was tested. Results: Out of 463 appli-
cations, 115 received positive recommendation (25%), 150 received restricted recom-
mendation (32%) and 198 (43%) were not recommended. Univariate analyses showed 
that 14 variables significantly affected the SMC decision. The multivariate analyses 
showed significant associations (p≤ 0.05) between the SMC decision and several 
variables, including: (1) a product demonstrating cost savings and QALY gains 
[OR= 6.11], (2) a product not being cost-effective (ICER≥ £30,000/QALY) [OR= 0.50], (3) 
a non-superior efficacy outcome versus placebo [OR= 0.15], (4) the product’s thera-
peutic indication (nervous system [OR= 0.51], blood forming organs [OR= 2.29]), (5) 
whether the product was indicated for non-chronic use [OR= 1.48] and (6) whether 
the submission was performed by a big company [OR= 1.86]. The proportional odds 
assumption was not violated, proving the appropriateness of the current model. The 
present model yielded similar results with the previously developed binary logistic 
one, further ensuring face validity, yet this approach is considered to better fit the 
multidimensional nature of SMC’s decision and increase the predictive power of 
the model. cOnclusiOns: This study identified superior efficacy using an active 
comparator as well as a beneficial cost-effectiveness outcome to increase the likeli-
hood of receiving a positive recommendation by the SMC.
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Objectives: The entrenched positioning of biologics to treat moderate-to-severe 
rheumatoid arthritis (RA) has generated a lucrative market. However, amid ongo-
ing economic constraints, the EU5 (France, Germany, Italy, Spain, and the UK) must 
tighten their health care belts. As biosimilars versions of key brands appear on 
the horizon, this study explored the expected impact of these cheaper options 
on reimbursement and prescribing for RA in each country. MethOds: Across the 
EU5, 254 rheumatologists were surveyed regarding their views on biosimilars for 
RA and on current and expected prescribing patterns. In addition, 15 payers who 
influence reimbursement at national or regional level were interviewed. Results: 
Considering 54-week Phase III data, ≥ 80% of surveyed rheumatologists in each coun-
try believe CT-P13 (biosimilar infliximab) has similar efficacy to branded Remicade; 
however, respondents are less confident in the biosimilar’s safety. Furthermore, 
> 80% of respondents in most countries are willing to prescribe biosimilars of inf-
liximab, and of etanercept and rituximab, though largely not before branded biolog-
ics. Unsurprisingly, given likely price discounts, interviewed payers will somewhat 
encourage biosimilar uptake. However, excluding those in Germany, consensus is 
that discounts offered on biosimilars will not significantly impact their budgets. 
German payers, however, report that additional rebates to statutory insurers are 
expected; they admit to financial incentives for physicians to prescribe rebated 
drugs, thus manufacturers may consider robust uptake will compensate for hefty 
discounts. cOnclusiOns: Available data have inspired prescriber confidence in 
biosimilar efficacy, although safety concerns, likely stemming from complex bio-
similar manufacturing and lack of long-term safety data, will ensure continued 
brand uptake, at least initially. Furthermore, the expected modesty of biosimilar 
discounts in most countries will somewhat curb payer policy promoting use of such 
agents. However, as prescribers become more familiar with biosimilars, and, as the 
full extent of cost savings are revealed, increasing uptake of biosimilars is probable.
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Objectives: Incentives are offered to pharmaceutical companies in order to 
increase the number of treatments for patients with rare diseases. As a conse-
quence, a number of new drugs have been introduced on the market—drugs that 
often fail to meet traditional cost-effectiveness criteria. This study aims to inves-
tigate if there are societal preferences for treating patients with rare diseases dif-
ferently in priority setting situations compared with common diseases. Moreover, 
psychological mechanisms that potentially could explain such preferences are 
explored. MethOds: A postal questionnaire in three versions was sent out to a 
representative sample of the general Swedish population. Respondents were asked 
to choose to give treatment to a patient with a rare or a common disease in eight 
different scenarios. Rarity of the disease, different alternative costs, and group/
individual level decisions was investigated. Psychological aspects in the presented 
scenaros that varied between subjects was related to proportion dominance, the 
identifiability of the patient, pseudo-inefficacy and if the scenario was expressed in 
priority or rationing terms. Results: Response rate was 41 % (n= 1239). For equal 
cost scenarios, 42.3 % were indifferent between the rare and the common group, 
23.9 % chose to prioritize the rare disease and 33.4 % the common disease. When 
questions were framed to be on an individul as opposed to a group level repond-
ents were significantly (p< .001) more likely to be indifferent. Proportion dominance 
increased individuals’ preferences to prioritize rare diseases (p< .001). Identifiability 
and pseudo-inefficacy had no major effect on respondents’ choices. cOnclusiOns: 
All else equal we see no strong support that a societal preference for rarity exists. 
However, we observe psychological effects influencing the judgments individuals 
make when setting priorities related to rare diseases. Whether or not these should 
quantify the value of using stratified information over population-based informa-
tion. Results: The incremental cost-effectiveness ratio (ICER) of CT versus X-ray 
was $31,942 per QALY, for the “average” trial patient, indicating that CT would be 
the preferred option at a cost-effectiveness threshold of $50,000 per QALY. However, 
when stratified into quintiles, CT is dominated for the lowest risk quintile (i.e., X-ray 
is the preferred option for quintile 1) and CT is preferred for higher risk groups (quin-
tiles 2 to 5). The EVIC was calculated at around $180 per person for cost-effectiveness 
thresholds of $50,000 per QALY and higher. cOnclusiOns: Tailoring screening 
strategies to avoid CT scan in the lowest risk quintile of patients appears to be a 
superior strategy compared to population-wide CT scan screening, although results 
were sensitive to the cost-effectiveness threshold and the level of granularity of the 
analysis. This study shows the value of considering the risk-based heterogeneity 
of cost-effectiveness in clinical guideline recommendations and policy decisions.
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Objectives: Self-monitoring of blood glucose (SMBG) may improve diabetes man-
agement. We analyzed the effect of SMBG on glycemic control, clinical outcomes 
and health care costs among insulin-users diabetic patients in a clinical practice 
setting. MethOds: A retrospective analysis using data from the administrative 
databases, clinical registries containing laboratory results and medical devices data-
bases including SMBG strips data of two Italian Local Health Units was performed. 
Insulin-users were defined if they had at least one prescription of insulin agents from 
November, 2009 and April, 2011. The first prescription was selected as index-date. 
Patients were divided into two groups based on testing frequency of SMBG during 
the 18 months after the index-date: no test strip claims (no SMBG use) and more 
than two test strips per day. We calculated incidence rates to estimate the risk for 
fasting blood glucose levels < 70 mg/dl and for diabetes-related hospitalizations or 
death occurrence during the 18-months follow-up period. Total annual costs included 
hypoglycemic therapy and the direct costs due to diabetes-related hospitalizations 
and outpatient services. Results: We identified 394 insulin-users patients with no 
SMBG use and 1350 with SMBG performed more than twice per day. Compared with 
non-SMBG use group, patients using SMBG showed a significant reduced risk of glu-
cose levels < 70 mg/dl (unadjusted rate was 10,6 vs 27,3 per 100 person-years, p< 0.001) 
and of diabetes-related hospitalizations or death (30,0 vs 60,8 per 100 person-years, 
p< 0.001). The higher hospitalization rate resulted in higher hospitalization costs per 
patient (€ 2.419 vs € 1.512 of those with SMBG use) and consequently higher total 
annual direct costs per patient (€ 3.060 vs € 2.738 of those using SMBG). cOnclusiOns: 
Results indicate that patients using SMBG, compared with non-SMBG patients, are 
associated with better glycemic control and reduced risk of diabetes-related hospi-
talizations and consequently with lower overall total annual cost per patient.
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Objectives: Anxiety and mood disorders are highly prevalent in Primary Care but 
research shows that general practitioners (GPs) fail to diagnose up to half of cases. In 
this study we try to determine the diagnostic accuracy of GPs’ diagnoses of anxiety 
disorders with and without any help from diagnostic (assisted vs unassisted diagno-
sis). MethOds: We searched for articles published from January 1980 to June 2014 in 
7 databases. We included studies in English, Spanish, French, and German reporting 
the ability of GPs to identify any anxiety disorder (DSM III/ IV/ IV-TR diagnostic crite-
ria) in Primary Care community samples. We excluded studies from general popula-
tion and those addressing specific physical or mental disorders, along with vignette 
and case-series studies. Two authors independently performed abstract and full-text 
reviews and data extraction. Study was assessed with the QUADAS-2. Coupled forest 
plots summarized estimated studies’ sensitivity and specificity and 95% confidence 
intervals. We fitted random-effects meta-analysis models and undertook a bivari-
ate meta-analysis to construct a summary Receiver Operator Characteristic Curve 
(sROC). Results: From a total 17.964 detected papers, 443 were included for full text 
review. So far, we have analyzed 111 papers, out of which 8 studies were included 
with N= 3608 patients with pooled anxiety prevalence 26% (CI= 25-27%). Preliminary 
results shows an overall ROC curve with lower GP diagnostic accuracy when per-
forming unassisted diagnoses for a total diagnostic accuracy 80% (CI= 79.4-80.1) with 
overall sensitivity= 49% (CI= 45-53), and Specificity = 92% (CI= 90-94). GP’s accuracy 
was higher with assisted diagnoses (86.7%, CI= 85%-89%) than unassisted diagnoses 
(45.5%; CI= 43.7%-47.3%). Specificity was lower in assisted (89.15%; CI= 87.9-90.4) 
than unassisted diagnosis (92.5%; CI= 91.9-93.1). cOnclusiOns: Low diagnostic 
sensitivity might hinder the adequate detection and management of anxiety in 
primary care. Results suggest that detection might be improved by using diagnostic 
tools. Results for all included articles will be presented.
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